Lymphoproliferative disorders after liver transplantation

Journal of Hepatology

Volumn 40, Issue 5, 2004, Pages 728-735

  Leblond, Véronique ^a   Choquet, Sylvain ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; B LYMPHOCYTE ANTIBODY; BLEOMYCIN; CD21 ANTIBODY; CD24 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; INTERLEUKIN 6 ANTIBODY; LYMPHOCYTE ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 1942471061     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.03.006     Document Type: Review

References (52)

1. Menachem Y., Safadi R., Ashur Y., Ilan Y. Malignancy after liver transplantation in patients with premalignant conditions. J Clin Gastroenterol. 36:2003;436-439.
2. Zein N.N., Perez R.G., Wiesner R.H. Hepatitis C virus infection and lymphoproliferative disorders. Hepatology. 31:2000;808-809.
3. Glez-Chamorro A., Jimenez C., Moreno-Glez E., Glez-Pinto I., Loinaz C., Gomez R., et al. Management and outcome of liver recipients with post-transplant lymphoproliferative disease. Hepato-Gastroenterol. 47:2000;211-219.
4. Duvoux C., Pageaux G.P., Vanlemmens C., Roudot-Thoraval F., Vincens-Rolland A.L., Hezode C., et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation. 74:2002;1103-1109.
5. Pageaux G.P., Bonnardet A., Picot M.C., Perrigault P.F., Coste V., Navarro F., et al. Prevalence of immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation. 65:1998;397-400.
6. Lemoine A., Pham P., Azoulay D., Saliba F., Emile J.F., Saffroy R., et al. Detection of gammapathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood. 98:2001;1332-1338.
7. Wu L., Rappaport D.C., Hanbidge A., Merchant N., Shepherd F.A., Greig P.D. Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging. 26:2001;200-206.
8. Jain A., Nalesnik M., Reyes J., Pokharna R., Mazariegos G., Green M., et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 236:2002;429-436.
9. Newell K.A., Alonso E.M., Kelly S.M., Rubin C.M., Thistlethwaite J.R. Jr, Whitington P.F. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 131:1997;98-104.
10. Cao S., Cox K., Esquivel C.O., Berquist W., Concepcion W., Ojogho O., et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation. 66:1998;851-856.
11. Smets F., Vajro P., Cornu G., reding R., Otte J.B., Sokal E. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation. 69:2000;982-984.
12. Guthery S.L., Heubi J.E., Bucuvalas J.C., Gross T.G., Ryckman F.C., Alons M.H., et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 75:2003;987-993.
13. Smets F., Latinne D., Bazin H., reding R., Otte J.B., Buts J.P., Sokal E.M. Ration between Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 73:2002;1603-1610.
14. Muti G., Mancini V., Veronese S., Poli F., Oreste P., Baldanti F., et al. Donor of recipient origin posttransplant lymphoproliferative disorders in liver transplanted patients: two different clinically relevant patterns of disease. Blood. 102:2003;629a. abst 2324.
15. Muti G., Klersy C., Baldanti F., Granata S., Oreste P., Pezzetti L., et al. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol. 122:2003;927-933.
16. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 3:2003;801-812.
17. Leblond V., Davi F., Charlotte F., Dorent R., Bitker M.O., Sutton L., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 16:1998;2052-2059.
18. Wu L., Rappaport D.C., Hanbidge A., Merchant N., Shepherd F.A., Greig P.D. Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging. 26:2001;200-206.
19. Koh B.Y., Rosenthal P., Medeiros L.J., Zhou Y., Osorio R.W., Roberts J.P., et al. Posttransplantation lymphoproliferative disorders in Childs undergoing liver transplantation. A clinicopathologic and molecular study. Arch Pathol Lab Med. 125:2001;337-343.
20. Doria C., Marino I.R., Scott V.L., Jaffe R., Minervi M.I., Zajko A., Nalesnik M.A. Posttransplant lymphoproliferative disorders presenting at sites of previous surgical intervention. Transplantation. 75:2003;1066-1069.
21. Baron P.W., Heneghan M.A., Suhocki P.V., Nuckols J.D., Tuttler-Newhall J.E., Howell D.N., Clavien P.A. Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation. Liver Transpl. 7:2001;62-67.
22. Harris N.L., Ferry J.A., Swerdlow S.H. Posttransplant lymphoproliferative disorders: summary of Society for hematopathology Workshop. Semin Diag Pathol. 14:1997;8-14.
23. Knowles D.M., Cesarman E., Chadburn A., Frizzera G., Chen J., Rose E., et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;552-565.
24. Milpied N., Vasseur B., Parquet N., Garnier J.L., Antoine C., Quartier P., et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 11:2000;113S-116S.
25. Choquet S., Leblond V., Herbrecht R., Socie G., Stoppa A.M., Vandenberghe P., et al. Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): final results of a multicenter, open label, phase II trial (M39037 TRIAL). Blood. 102:2003;277a.
26. Rooney C.M., Heslop H.E., Brenner M.K. EBV specific CTL: a model for immune therapy. Vox Sanguinis. 74:1998;497-498.
27. Fridell J.A., Jain A., Reyes J., Biederman R., Green M., Sindhi R., et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. Transplantation. 74:2002;1721-1724.
28. Jain A., Mazariegos G., Kashyap R., Kosmach-Park B., Starzl T.E., Fung J., et al. Pediatric liver transplantation: a single center experience spanning 20 years. Transplantation. 73:2002;941-947.
29. Leblond V., Dhedin N., Mamzer Bruneel M.F., Choquet S., Hermine O., Porcher R., et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 19:2001;772-778.
30. Ghobrial I.M., Habermann T.M., Maurer M.J., Geyer S.M., Macon W., Ristaw K. Proposed prognostic model for survival in solid organ transplant recipients with posttransplant lymphoproliferative disorders (PTLD). Blood. 102:2003;392a. abst 1423.
31. Tsai D.E., Hardy C.L., Tomaszewski J.E., Kotloff R.M., Oltoff K.M., Somer B.G., et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adults patients. Transplantation. 71:2001;1076-1108.
32. Oertel S.H., Anagnostopoulos I., Hummel M.W., Jonas S., Riess H.B. Identification of early antigen BZLF1/ZEBRA protein of Epstein Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Hematol. 118:2002;1120-1123.
33. Darenkov I.A., Marcarelli M.A., Basadonna G.P., Friedman A.L., Lorber K.M., Howe J.G., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation. 64:1997;848-852.
34. Choquet S., Leblond V., Jager U., Riess H., Levy V., Raphael M., et al. Efficacy of CHOP regimen as first line therapy in posttransplantation lymphoproliferative disorders (PTLD). A retrospective study on 25 cases. Blood. 102:2003;49b. abst 3897.
35. Gross T.G., Park J., Bucuvalas J., Langnas A., Kaufman S., McDonald R., et al. Low-dose chemotherapy for refractory EBV associated post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) in children. Blood. 100:2002;159a. abst 598.
36. Cacciarelli T.V., Green M., Jaffe R., Mazariegos G.V., Jain A., Fung J.J., et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 66:1998;1047-1052.
37. Davis C.L., Wood B.L., Sabath D.E., Joseph J.S., Stehman-Breen C., Broudy V.C. Interferon-alpha treatment of post-transplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 66:1998;1770-1779.
38. Haddad E., Paczesny S., Leblond V., Seigneurin J.M., Stern M., Achkar A., et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase1-2 clinical trial. Blood. 97:2001;1590-1597.
39. Benkerrou M., Jais J.P., Leblond V., Durandy A., Sutton L., Bordigoni P., et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 92:1998;3137-3147.
40. Straathof K.C., Savoldo K.C., Heslop H.E., Rooney C.M. Immunotherapy for post-transplant lymphoproliferative disease. Br J Hematol. 118:2002;728-740.
41. Zompi S., Tulliez M., Conti F., Leblond V., Gaulard P., Blanche S., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthoptic liver transplantation: a report of three cases. J Hepatol. 32:2000;521-527.
42. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 92:1998;1549-1555.
43. Nalesnik M.A., Rao A.S., Furukawa H., Pham S., Zeevi A., Fung J.J. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation. 63:1997;1200-1205.
44. Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S., Rafter L., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with post transplant lymphoproliferative disease. Proc Natl Acad Sci USA. 96:1999;10391-10396.
45. Comoli P., Labirio M., Basso S., Baldanti F., Grossi P., Furione M., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 99:2002;2592-2598.
46. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Lley A., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 360:2002;436-442.
47. Mutimer D., Kaur N., Tang H., Singhal S., Shaw J., Whitehead L., et al. Quantification of Epstein-Barr virus DNA in the blood after adult liver transplantation. Transplantation. 69:2000;954-959.
48. Kogan-Liberman D., Burroughs M., Emre S., Moscona A., Shneider B.I. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr. 33:2001;445-449.
49. Gridelli B., Spada M., Riva S., Colledan M., Segalin A., Lucianetti A., et al. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation. Transplant Inter. 13:2000;399-401s.
50. Van Esser W.J., Niesters H.G.M., Van der Holt B., Meijer E., Osterhaus A.D., Gratama J.W., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive Rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 99:2002;4364-4369.
51. Holmes R.D., Orban-Eller K., Karrer F.R., Rowe D.T., Narkewicz M.R., Sokol R.J. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56 months follow-up and outcome. Transplantation. 74:2002;367-372.
52. Smets F., Latinne D., Bazin H., reding R., Otte J.B., Buts J.P., Sokal E.M. Ration between Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 73:2002;1603-1611.